Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis

Efficacy of abrocitinib monotherapy by body location in patients with moderate-to-severe atopic dermatitis: pooled results from phase 2b/3 studies

book_2 Source: EADV Virtual - Poster session
calendar_today Published on Medfyle: November 2020
headphones 4 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Abrocitinib is a once-daily oral JAK inhibitor under investigation for AD.
  • In this pooled analysis, patients treated with abrocitinib had greater improvements in extent and severity of AD in all body locations compared to placebo.
  • Abrocitinib delivered change from baseline in erythema, induration, papulation, excoriation and lichenification.
  • Dose-dependent reductions were consistent across all AD signs measured by EASI.
Presenting Author
Read more arrow_downward Hide arrow_upward

Jonathan I. Silverberg
George Washington University School of Medicine and Health Sciences, Washington, DC, USA


Feedback